EA200401355A1 - Применение циклопамина при лечении псориаза и других кожных заболеваний - Google Patents

Применение циклопамина при лечении псориаза и других кожных заболеваний

Info

Publication number
EA200401355A1
EA200401355A1 EA200401355A EA200401355A EA200401355A1 EA 200401355 A1 EA200401355 A1 EA 200401355A1 EA 200401355 A EA200401355 A EA 200401355A EA 200401355 A EA200401355 A EA 200401355A EA 200401355 A1 EA200401355 A1 EA 200401355A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cyclopamine
treatment
corticosteroid
skin
lesions
Prior art date
Application number
EA200401355A
Other languages
English (en)
Inventor
Шинан Таш
Октай Авси
Original Assignee
Шинан Таш
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29247069&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200401355(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/TR2002/000017 external-priority patent/WO2002078704A1/en
Application filed by Шинан Таш filed Critical Шинан Таш
Publication of EA200401355A1 publication Critical patent/EA200401355A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Фармацевтические композиции, содержащие циклопамин, способствуют преодолению ингибирования дифференцировки клеток кожи. Такие композиции эффективны при лечении болезней, связанных с нарушенной клеточной дифференцировкой. В случае опухолей индукция дифференцировки опухолевых клеток циклопамином обычно сопровождается апоптозом опухолевых клеток, усиливая тем самым терапевтическую эффективность. Эффективность циклопамина при лечении псориаза, обычного заболевания, связанного с нарушением клеточной дифференцировки, значительно повышается при использовании композиций, состоящих из циклопамина и кортикостероида.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200401355A 2002-04-19 2003-03-17 Применение циклопамина при лечении псориаза и других кожных заболеваний EA200401355A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/TR2002/000017 WO2002078704A1 (en) 2001-07-02 2002-04-19 Use of cyclopamine in the treatment of psoriasis
PCT/TR2003/000017 WO2003088964A1 (en) 2002-04-19 2003-03-17 Use of cyclopamine in the treatment of psoriasis and other skin disorders

Publications (1)

Publication Number Publication Date
EA200401355A1 true EA200401355A1 (ru) 2005-06-30

Family

ID=29247069

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200401355A EA200401355A1 (ru) 2002-04-19 2003-03-17 Применение циклопамина при лечении псориаза и других кожных заболеваний

Country Status (15)

Country Link
US (6) US7893078B2 (ru)
EP (2) EP1411938B1 (ru)
JP (1) JP2006512281A (ru)
KR (4) KR20080096605A (ru)
CN (2) CN1835748A (ru)
AT (1) ATE309802T1 (ru)
AU (1) AU2003230541B2 (ru)
BR (1) BR0309396A (ru)
CA (3) CA2452152A1 (ru)
DE (1) DE60302348T2 (ru)
DK (1) DK1496895T3 (ru)
EA (1) EA200401355A1 (ru)
ES (1) ES2253672T3 (ru)
MX (1) MXPA04010294A (ru)
WO (1) WO2003088964A1 (ru)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291626B1 (en) 1998-04-09 2007-11-06 John Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
CA2386190C (en) 1999-10-13 2009-04-14 Johns Hopkins University School Of Medicine Regulators of the hedgehog pathway, compositions and uses related thereto
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US20170326118A1 (en) * 2001-07-02 2017-11-16 Sinan Tas Drug treatment of tumors wherein hedgehog/smoothened signaling is utilized for inhibition of apoptosis of tumor cells
EP2862570A1 (en) * 2001-07-02 2015-04-22 Sinan Tas Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
EP1411938B1 (en) * 2001-07-02 2005-07-06 Tas, Sinan Use of cyclopamine for the manufacture of a medicament for the treatemnt of psoriasis
ES2578728T3 (es) 2004-08-27 2016-07-29 Infinity Pharmaceuticals, Inc. Proceso para la preparación de compuestos análogos de ciclopamina
JP2008514726A (ja) * 2004-09-30 2008-05-08 ザ ユニヴァーシティー オヴ シカゴ ヘッジホッグ阻害剤、放射線及び化学療法薬の併用療法
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
EP2511298B1 (en) 2005-10-31 2019-01-16 Oncomed Pharmaceuticals, Inc. Compositions and Methods for Treating Cancer based on human FZD receptors
US20090156611A1 (en) * 2005-11-11 2009-06-18 Licentia Ltd. Mammalian hedgehog signaling modulators
EP1998785A4 (en) * 2006-02-21 2009-06-17 Univ Michigan TREATMENT OF CANCER BY AN ANTAGONIST OF THE HEDGEHOG SIGNALING PATH
US20110034498A1 (en) * 2006-03-24 2011-02-10 Mcgovern Karen J Dosing regimens for the treatment of cancer
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
WO2008092002A2 (en) 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
WO2008109184A1 (en) * 2007-03-07 2008-09-12 Infinity Pharmaceuticals, Inc. Heterocyclic cyclopamine analogs and methods of use thereof
JP2010520310A (ja) 2007-03-07 2010-06-10 インフィニティ・ディスカバリー・インコーポレイテッド シクロパミンラクタム類似体及びその使用方法
US20090181997A1 (en) * 2007-12-27 2009-07-16 Grayzel David Therapeutic cancer treatments
US20100297118A1 (en) * 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
CN104059124A (zh) 2007-12-27 2014-09-24 无限药品股份有限公司 立体选择性还原的方法
CN101990542A (zh) * 2008-02-08 2011-03-23 德克萨斯大学董事会 环巴胺酒石酸盐及其用途
GB0813740D0 (en) * 2008-07-28 2008-09-03 Angeletti P Ist Richerche Biologica Therapeutic compounds
TWI506037B (zh) 2008-09-26 2015-11-01 Oncomed Pharm Inc 捲曲結合劑類及彼等之用途
US20110275576A1 (en) * 2009-01-06 2011-11-10 Utah State University Carbohydrate-Cyclopamine Conjugates as Anticancer Agents
GB0900484D0 (en) 2009-01-13 2009-02-11 Angeletti P Ist Richerche Bio Therapeutic agent
JP6141015B2 (ja) 2009-08-05 2017-06-07 インフィニティ ファーマスーティカルズ、インク． シクロパミン類似体の酵素によるアミノ基転移
GB0916608D0 (en) 2009-09-22 2009-11-04 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2501237A1 (en) * 2009-11-06 2012-09-26 Infinity Pharmaceuticals, Inc. Oral formulations of a hedgehog pathway inhibitor
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
US20110183948A1 (en) * 2010-01-15 2011-07-28 Infinity Pharmaceuticals, Inc. Treatment of fibrotic conditions using hedgehog inhibitors
WO2011123785A2 (en) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
US9376447B2 (en) 2010-09-14 2016-06-28 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
EP2911691B1 (en) 2012-10-23 2018-10-10 OncoMed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
HRP20251395T1 (hr) 2015-06-04 2026-02-13 Sol-Gel Technologies Ltd. Topikalne formulacije za isporuku spojeva inhibitora hedgehog signalnog puta i njihova uporaba
AU2018205253B2 (en) 2017-01-06 2022-01-13 Palvella Therapeutics, Inc. Anhydrous compositions of mTOR inhibitors and methods of use
EP3817743A4 (en) 2018-07-02 2022-07-06 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE
WO2020118095A1 (en) 2018-12-06 2020-06-11 OctoTech, Inc. Rf receiver architectures with parametric circuits
JP2024522808A (ja) * 2021-06-21 2024-06-21 パルヴェラ セラピューティクス、インク． ゴーリン症候群を治療するための方法および組成物
CN117940170A (zh) 2021-09-13 2024-04-26 辛南·塔斯 有效干预人类衰老和衰老疾病及其效果

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH649923A5 (de) * 1980-10-06 1985-06-28 Glaxo Group Ltd Topisch verabreichbare pharmazeutische zusammensetzungen, enthaltend anti-inflammatorische steroide.
US5891465A (en) * 1996-05-14 1999-04-06 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
DE69841320D1 (de) 1997-02-10 2010-01-07 Harvard College Verfahren zur modulation von hämatopoese und vaskulärem wachstum
US6238876B1 (en) 1997-06-20 2001-05-29 New York University Methods and materials for the diagnosis and treatment of sporadic basal cell carcinoma
US20050130922A1 (en) 1997-06-20 2005-06-16 Altaba Ariel R.I. Method and compositions for inhibiting tumorigenesis
US7741298B2 (en) 1997-06-20 2010-06-22 New York University Method and compositions for inhibiting tumorigenesis
US7291626B1 (en) * 1998-04-09 2007-11-06 John Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
US6867216B1 (en) * 1998-04-09 2005-03-15 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signal pathways, compositions and uses related thereto
US6432970B2 (en) * 1998-04-09 2002-08-13 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
CA2326654C (en) * 1998-04-09 2010-11-09 Johns Hopkins University School Of Medicine Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
US6291516B1 (en) * 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
ES2233383T3 (es) * 1999-06-08 2005-06-16 Lorantis Limited Utilizacion terapeutica de un ihibidor de la via de señalizacion hedgehog.
US20050080138A1 (en) 1999-09-16 2005-04-14 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
CA2386190C (en) * 1999-10-13 2009-04-14 Johns Hopkins University School Of Medicine Regulators of the hedgehog pathway, compositions and uses related thereto
US6552016B1 (en) 1999-10-14 2003-04-22 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
AU1935801A (en) * 1999-11-30 2001-06-12 Curis, Inc. Methods and compositions for regulating lymphocyte activity
US6951839B1 (en) * 1999-11-30 2005-10-04 Curis, Inc. Methods and compositions for regulating lymphocyte activity
US6683108B1 (en) 2000-03-30 2004-01-27 Curis, Inc. Agonists of hedgehog signaling pathways and uses related thereto
US7115653B2 (en) 2000-03-30 2006-10-03 Curis, Inc. Small organic molecule regulators of cell proliferation
AU7549501A (en) 2000-06-16 2002-01-02 Biogen Inc Angiogenesis-modulating compositions and uses
US7498304B2 (en) 2000-06-16 2009-03-03 Curis, Inc. Angiogenesis-modulating compositions and uses
CU23175A1 (es) * 2000-07-17 2006-09-22 Ct De Investigacion Y Desarrol Formulacion liposomica de propionato de clobetasol
US20020165221A1 (en) 2000-10-13 2002-11-07 Baxter Anthony David Mediators of hedgehog signaling pathways, compositions and uses related thereto
AU9684401A (en) 2000-10-13 2002-04-22 Curis Inc Hedgehog antagonists, methods and uses related thereto
US7708998B2 (en) 2000-10-13 2010-05-04 Curis, Inc. Methods of inhibiting unwanted cell proliferation using hedgehog antagonists
JP2004534743A (ja) 2001-04-09 2004-11-18 ロランティス リミテッド ヘッジホッグ
EP1411938B1 (en) * 2001-07-02 2005-07-06 Tas, Sinan Use of cyclopamine for the manufacture of a medicament for the treatemnt of psoriasis
EP2862570A1 (en) * 2001-07-02 2015-04-22 Sinan Tas Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
MXPA04003266A (es) * 2001-10-05 2004-07-08 Combinatorx Inc Combinaciones para el tratamiento de desodrdenes inmuno-inflamatorios.
US6927205B2 (en) * 2003-04-28 2005-08-09 Procyte Corporation Compositions and methods for treatment of psoriasis
KR20050037103A (ko) 2003-10-17 2005-04-21 주식회사 엘지생활건강 피부 미백용 화장료 조성물
ES2578728T3 (es) * 2004-08-27 2016-07-29 Infinity Pharmaceuticals, Inc. Proceso para la preparación de compuestos análogos de ciclopamina
US8653083B2 (en) * 2005-08-22 2014-02-18 The Johns Hopkins University Hedgehog pathway antagonists to treat disease

Also Published As

Publication number Publication date
US20090286822A1 (en) 2009-11-19
JP2006512281A (ja) 2006-04-13
US20040072913A1 (en) 2004-04-15
BR0309396A (pt) 2005-02-09
US9757361B2 (en) 2017-09-12
MXPA04010294A (es) 2005-05-17
DE60302348D1 (de) 2005-12-22
US20110104254A1 (en) 2011-05-05
AU2003230541A1 (en) 2003-11-03
EP1496895B1 (en) 2005-11-16
KR20040102117A (ko) 2004-12-03
KR20070108287A (ko) 2007-11-08
US20080090790A1 (en) 2008-04-17
DE60302348T2 (de) 2006-07-27
CN101642458A (zh) 2010-02-10
CA2636960C (en) 2013-12-31
WO2003088964A1 (en) 2003-10-30
US7629352B2 (en) 2009-12-08
US20100048725A2 (en) 2010-02-25
CN1835748A (zh) 2006-09-20
KR20080096605A (ko) 2008-10-30
CA2481499C (en) 2013-05-21
US7893078B2 (en) 2011-02-22
ES2253672T3 (es) 2006-06-01
EP1411938B1 (en) 2005-07-06
CA2452152A1 (en) 2002-10-10
CA2481499A1 (en) 2003-10-30
US7605167B2 (en) 2009-10-20
CA2636960A1 (en) 2003-10-30
EP1411938A1 (en) 2004-04-28
EP1496895A1 (en) 2005-01-19
DK1496895T3 (da) 2006-03-27
US20080089915A1 (en) 2008-04-17
ATE309802T1 (de) 2005-12-15
US20040072914A1 (en) 2004-04-15
US8025893B2 (en) 2011-09-27
KR20080094739A (ko) 2008-10-23
AU2003230541B2 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
BR0309396A (pt) Uso de ciclopamina no tratamento de psorìase e outros distúrbios da pele
CY1121447T1 (el) Συνθεσεις για αυξηση δραστηριοτητας τελομερασης
IL172705A0 (en) Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases
Gobello et al. Medium-versus high-dose ultraviolet A1 therapy for urticaria pigmentosa: a pilot study
MX9306239A (es) Composicion farmaceutica que forma un gel de lecitina in vivo para la liberacion mantenida de un compuesto biologicamente activo y procedimiento para la preparacion de la misma.
EP1819227A4 (en) PHARMACEUTICAL FORMULATIONS OF DECITABIN
EA200001044A3 (ru) Соединения для лечения женской сексуальной дисфункции
BRPI0412493A (pt) métodos de tratamento hormonal utilizando regimes contraceptivos com administração contìnua de estrogênio
Joseph et al. Unilateral remission of psoriasis following traumatic nerve palsy
BR0209922A (pt) Método para tratar uma condição médica que envolve a angiogênese em um paciente, para inibir a vascularização de células endoteliais, e para tratar câncer em um mamìfero
EP1543158A4 (en) REGULATED APTAMER THERAPEUTICS
DE60140960D1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
MY134562A (en) Methods and compositions to treat conditions associated with neovascularization
ES2187646T3 (es) Procedimientos para el tratamiento de inflamaciones y composiciones correspondientes.
DE60115432D1 (de) Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
DK1558265T3 (da) Anvendelse af dropspirenon til behandling af hypertension
WO2003056899A3 (en) Nitric oxide donors for treatment of disease and injury
TW200501934A (en) Therapeutic causing contraction of mucosal tissue, method of treating diseases relating to mucosal tissues, injector and therapeutic set
US20240300945A1 (en) Cly series compound, preparation method therefor and use thereof in preparation of drugs
ATE556134T1 (de) Mesenchymstammzellen und verwendungendafür
PT1251850E (pt) Utilizacao de uma preparacao de combinacao na terapia do cancro
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
ATE320797T1 (de) Verwendung von 6-dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz
EA200500427A1 (ru) Способы лечения пациентов, страдающих синдромом усталых ног или связанными с ним заболеваниями
WO2004012677A3 (en) Methods and compositions to treat conditions associated with neovascularization